ClinicalTrials.gg
CompletedNCT03525613Updated Jul 6, 2023Results posted

A Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration

A Phase 3 interventional study of APL-2 and APL-2 in Geographic Atrophy, sponsored by Apellis Pharmaceuticals, Inc.. Completed at 112 sites in 14 countries. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2023-07-06.

Sponsored by Apellis Pharmaceuticals, Inc. (part of Biogen) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
637
Allocation
Randomized
Ages
60 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 131 studies in Geographic Atrophy with a site in United States — 35 open to participants now, 45 under way, 5 of them phase 3. Geographic Atrophy · United States.

Enrollment
8th of 107
637 · median 98
Started
2018
with 7 others
Phase 3
15 of 131
2 open now
Registered
53rd of 131
by date
Lead sponsor
8 of 131
Apellis Pharmaceuticals, Inc.

Among the 131 studies in Geographic Atrophy with a site in United States, this one is the 8th largest by enrollment of the 107 interventional ones that give a count, is one of 8 that started in 2018, is one of 15 in phase 3, and was the 53rd registered.

Geographic Atrophy

188 studies on the registry are indexed under Geographic Atrophy; 52 are open to participants now.

Browse Geographic Atrophy studies →

Open to participants now

35 of the 131 studies in Geographic Atrophy with a site in United States are open now. Recruiting first, the newest first:

30 more — sign in →

All 35 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 40 Geographic Atrophy studies recruiting now, 31 (78%) set no upper age limit and none (0%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.

This study: 60 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 131 studies in Geographic Atrophy with a site in United States, or all of them as a file.
02

Study summary

This is a 24-month, Phase III, multicenter, randomized, double-masked, sham-injection controlled study to assess the efficacy and safety of multiple IVT injections of APL-2 in subjects with GA secondary to AMD.

03

Conditions studied

  • Geographic Atrophy

Browse trials for

04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

The study eye must meet all inclusion criteria. If both eyes meet the inclusion criteria, the eye with the worst visual acuity at the screening visit will be designated as the study eye. If both eyes have the same visual acuity, the right eye will be selected as the study eye.

Ocular- specific inclusion criteria apply to the study eye only, unless otherwise specified.

  • Age ≥ 60 years.
  • Normal Luminance best corrected visual acuity of 24 letters or better using Early Treatment Diabetic Retinopathy Study (ETDRS) charts (approximately 20/320 Snellen equivalent).
  • Clinical diagnosis of GA of the macula secondary to AMD as determined by the Investigator and confirmed by the Reading Center.
  • The GA lesion must meet the following criteria as determined by the central reading center's assessment of Fundus Autofluorescence (FAF) imaging at screening:

    • Total GA area must be ≥ 2.5 and ≤ 17.5 mm2 (1 and 7 disk areas [DA] respectively)
    • If GA is multifocal, at least one focal lesion must be ≥ 1.25 mm2 (0.5 DA), with the overall aggregate area of GA, as specified above in 4a.
    • The entire GA lesion must be completely visualized on the macula centered image and must be able to be imaged in its entirety and not contiguous with any areas of peripapillary atrophy.
    • Presence of any pattern of hyperautofluorescence in the junctional zone of GA. Absence of hyperautofluorescence (i.e. pattern = none) is exclusionary.
  • Adequate clarity of ocular media, adequate pupillary dilation, and fixation to permit the collection of good quality images as determined by the Investigator.
  • Meets the following criteria related to microperimetry:

    • Able to detect fixation target.
    • Total elapsed time to complete the 10-2 68 point exam is ≤ 30 minutes in duration.
    • Reliability test ratio must be ≤ 20%.
    • Subject is willing and able to undertake microperimetry assessment in the opinion of the investigator.
  • Female subjects must be:

    • Women of non- (WONCBP), or
    • Women of child-bearing potential (WOCBP) with a negative pregnancy test at screening and must agree to use protocol defined methods of for the duration of the study and refrain from breastfeeding for the duration of the study.
  • Males with female partners of child-bearing potential must agree to use protocol defined methods of contraception and agree to refrain from donating sperm for the duration of the study.
  • Willing and able to give and to comply with the study procedures and assessments.

Exclusion criteria

Exclusion Criteria:

Ocular specific exclusion criteria apply to the study eye only, unless otherwise specified.

  • GA secondary to a condition other than AMD such as Stargardt disease, cone rod dystrophy or toxic maculopathies like plaquenil maculopathy in either eye.
  • Spherical equivalent of the refractive error demonstrating > 6 diopters of myopia or an axial length >26 mm.
  • Any history or active choroidal neovascularization (CNV), associated with AMD or any other cause, including any evidence of retinal pigment epithelium rips or evidence of neovascularization anywhere based on SD-OCT imaging and/or fluorescein angiography as assessed by the Reading Center.
  • Presence of an active ocular disease that in the opinion of the Investigator compromises or confounds visual function, including but not limited to, uveitis, other macular diseases (e.g. epiretinal membrane (ERM), full thickness macular hole or uncontrolled glaucoma/ocular hypertension. Benign conditions in the opinion of the investigator such as peripheral retina dystrophy are not exclusionary).
  • Intraocular surgery (including lens replacement surgery) within 3 months prior to randomization.
  • History of laser therapy in the macular region.
  • Aphakia or absence of the posterior capsule. Note: YAG laser posterior capsulotomy for posterior capsule opacification done at least 60 days prior to screening is not exclusionary.
  • Any ocular condition other than GA secondary to AMD that may require surgery or medical intervention during the study period or, in the opinion of the Investigator, could compromise visual function during the study period.
  • Any to IVT injection including current ocular or periocular infection.
  • History of prior intravitreal injection.
  • Unable to perform microperimetry reliably in the opinion of the investigator
  • Prior participation in another interventional clinical study for intravitreal therapies in either eye (including subjects receiving sham).
  • Prior participation in another interventional clinical study for geographic atrophy in either eye including oral medication and placebo.
  • Participation in any systemic experimental treatment or any other systemic investigational new drug within 6 weeks or 5 half-lives of the active ingredient (whichever is longer) prior to the start of study treatment. Note: clinical trials solely involving observation, over-the-counter vitamins, supplements, or diets are not exclusionary.
  • Medical or psychiatric conditions that, in the opinion of the investigator, make consistent follow-up over the 24-month treatment period unlikely, or would make the subject an unsafe study candidate.
  • Any screening laboratory value (hematology, serum chemistry or urinalysis) that in the opinion of the Investigator is clinically significant and not suitable for study participation.
  • Known to fluorescein sodium for injection or hypersensitivity to APL-2 or any of the in APL-2 solution.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
637 participants (actual)

Study arms

  • Experimental
    APL-2 15mg 0.1 mL Monthly for 24 months

    A single dose of 15 mg APL-2/0.1 mL will be administered via intravitreal injection in this study. Subjects will receive an injection every month

    Drug: APL-2

  • Experimental
    APL-2 15mg 0.1 mL EOM for 24 months

    A single dose of 15 mg APL-2/0.1 mL will be administered via intravitreal injection in this study. Subjects will receive an injection every other month

    Drug: APL-2

  • Experimental
    Sham Procedure Monthly for 24 months

    Sham Procedure monthly for 24 months

    Other: Sham Procedure

  • Experimental
    Sham Procedure Every Other Month for 24 months

    Sham Procedure every other month for 24 months

    Other: Sham Procedure

Interventions

  • DrugAPL-2

    Complement (C3) Inhibitor

    Also known as: Pegcetacoplan

  • DrugAPL-2

    Complement (C3) Inhibitor

    Also known as: Pegcetacoplan

  • OtherSham Procedure

    Subjects will receive a Sham procedure every month

  • OtherSham Procedure

    Subjects will receive a Sham procedure every other month

06

What researchers measure

Primary outcomes

  1. Least Squares (LS) Mean Change From Baseline in Total Area of GA Lesions in the Study Eye at Month 12

    The GA lesion area was measured by a quantified central reading center based on FAF images. LS mean was calculated using a mixed effect model for repeated measure (MMRM) model. Baseline was defined as the last available, non-missing observation prior to first study drug administration.

    Time frame: Baseline (screening) and Month 12

Secondary outcomes

  1. LS Mean Change From Baseline in Total Area of GA Lesions in the Study Eye at Month 24

    The GA lesion area was measured by a quantified central reading center based on FAF images. LS mean was calculated using a mixed effect model for repeated measure model. Baseline was defined as the last available, non-missing observation prior to first study drug administration.

    Time frame: Baseline (screening) and Month 24

  2. Mean Change in Total Area of GA Lesions in the Study Eye Through Month 24

    The mean change in GA lesion area through Month 24 was measured by assuming a piecewise linear trend in time with knots by FAF images at Months 6, 12, 18, and 24 and was calculated using a MMRM model. Baseline was defined as the last available, non-missing observation prior to first study drug administration.

    Time frame: From Baseline (screening) through Month 24

  3. LS Mean Change From Baseline in Mean Threshold Sensitivity of All Points of the Study Eye at Month 24

    Mean threshold sensitivity of all points was determined from the mesopic microperimetry as an assessment of the macular functional response. Microperimetry offers the option to test retinal light sensitivity while directly observing the fundus and allows for monitoring of macular function loss associated with GA progression. The microperimetry reading center overlaid the baseline FAF images with GA lesions traced by the imaging reading center and the corresponding macular integrity assessment microperimetry baseline scanning laser ophthalmoscope image and identified perilesional (within 500 microns outside the atrophy border), paralesional (beyond 500 microns outside the atrophy border), and extralesional (outside the atrophy border) loci on the microperimetry grid to determine the mean threshold sensitivity for these 3 areas. LS mean was calculated using a MMRM model. Baseline was defined as the last available, non-missing observation prior to first study drug administration.

    Time frame: Baseline (screening) and Month 24

  4. LS Mean Change From Baseline in Monocular Maximum Reading Speed of the Study Eye at Month 24

    The maximum reading speed of the study eye was calculated per Minnesota Low-Vision Reading Test (MNREAD) or Radner Reading Charts user manuals, with no adjustment for reading inaccuracy. An additional step to cap resulting reading speed values at a maximum of 300 words per minute (wpm) was implemented. Maximum reading speed was calculated as the mean of the 3 highest non-zero reading speeds (or 2, or 1 value, as available), except when all wpm were calculated as 0 then the maximum reading speed was calculated as 0. LS mean was calculated using a MMRM model. Baseline was defined as the last available, non-missing observation prior to first study drug administration.

    Time frame: Baseline (screening) and Month 24

  5. LS Mean Change From Baseline in Mean Functional Reading Independence (FRI) Index Score at Month 24

    The FRI was an interviewer-administered questionnaire with 7 items on functional reading activities most relevant to GA AMD subjects. It had 1 total index score. For each FRI Index reading activity performed in the past 7 days, subjects were asked about the extent to which they required assistance beyond eyeglasses/contact lenses, including the use of low-vision aids, adjustments in the activity, or help from another subject. Mean FRI Index scores ranged from 1 (unable to do independently) to 4 (totally independent), with higher scores indicating higher functional reading independence. A negative change from baseline indicated a decrease in the FRI; disease worsening. LS mean was calculated using a MMRM model. Baseline was defined as the last available, non-missing observation prior to first study drug administration.

    Time frame: Baseline (screening) and Month 24

  6. LS Mean Change From Baseline in Normal-Luminance Best-Corrected Visual Acuity (NL-BCVA) Score of the Study Eye at Month 24

    The NL-BCVA was assessed by early treatment diabetic retinopathy study (ETDRS) chart prior to dilating the eyes at a starting distance of 4 meters and ranged from 0 (least score) to 100 (best score). If the 4-meter score was \>19 letters read correctly, the visual acuity score was the sum of total letters correctly read at 4 meters plus the addition of 30. If the 4-meter score was ≤19 letters read correctly, the visual acuity score was the sum of total letters read correctly at 4 meters and total letters read correctly at the 1-meter distance. If no letters were read correctly at either the 4-meter distance or the 1-meter distance, the visual acuity score was 0. A positive change in the value indicated improvement in visual acuity. LS mean was calculated using a MMRM model. Baseline was defined as the last available, non-missing observation prior to first study drug administration.

    Time frame: Baseline (screening) and Month 24

07

Results

Posted Jul 6, 2023

Participant flow

This Phase III, randomized, double-masked, sham injection-controlled study was conducted in subjects with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) at 110 sites in 13 countries between 31 Aug 2018 and 28 Jun 2022.

Participant flow — Overall Study
MilestonePegcetacoplan MonthlyPegcetacoplan EOMSham MonthlySham EOM
Started213212106106
Completed1441697682
Not completed69433024
Withdrew: Adverse event11833
Withdrew: Lost to follow-up4532
Withdrew: Physician decision0101
Withdrew: Consent withdrawal2516129
Withdrew: Death20971
Withdrew: Due to coronavirus disease-2019 (covid-19) impact9458

Outcome measures

PrimaryLeast Squares (LS) Mean Change From Baseline in Total Area of GA Lesions in the Study Eye at Month 12

The GA lesion area was measured by a quantified central reading center based on FAF images. LS mean was calculated using a mixed effect model for repeated measure (MMRM) model. Baseline was defined as the last available, non-missing observation prior to first study drug administration.

Time frame:
Baseline (screening) and Month 12
Reported as:
Least squares mean · mm^2
Least Squares (LS) Mean Change From Baseline in Total Area of GA Lesions in the Study Eye at Month 12
mm^2Pegcetacoplan MonthlyPegcetacoplan EOMSham Pooled
Least Squares (LS) Mean Change From Baseline in Total Area of GA Lesions in the Study Eye at Month 121.5579 ± 0.083501.6512 ± 0.081181.9692 ± 0.08218
Statistical analysis
  • Pegcetacoplan Monthly vs Sham Pooled · MMRM model · p = 0.0004 · Ls mean difference: -0.4114 · 95% CI -0.6397 to -0.1831
  • Pegcetacoplan EOM vs Sham Pooled · MMRM model · p = 0.0055 · Ls mean difference: -0.3180 · 95% CI -0.5423 to -0.0937
SecondaryLS Mean Change From Baseline in Total Area of GA Lesions in the Study Eye at Month 24

The GA lesion area was measured by a quantified central reading center based on FAF images. LS mean was calculated using a mixed effect model for repeated measure model. Baseline was defined as the last available, non-missing observation prior to first study drug administration.

Time frame:
Baseline (screening) and Month 24
Reported as:
Least squares mean · mm^2
LS Mean Change From Baseline in Total Area of GA Lesions in the Study Eye at Month 24
mm^2Pegcetacoplan MonthlyPegcetacoplan EOMSham Pooled
LS Mean Change From Baseline in Total Area of GA Lesions in the Study Eye at Month 243.1237 ± 0.143273.2826 ± 0.132384.0252 ± 0.14642
Statistical analysis
  • Pegcetacoplan Monthly vs Sham Pooled · MMRM model · p = <0.0001 · Ls mean difference: -0.9015 · 95% CI -1.3026 to -0.5004
  • Pegcetacoplan EOM vs Sham Pooled · MMRM model · p = 0.0002 · Ls mean difference: -0.7426 · 95% CI -1.1282 to -0.3570
SecondaryMean Change in Total Area of GA Lesions in the Study Eye Through Month 24

The mean change in GA lesion area through Month 24 was measured by assuming a piecewise linear trend in time with knots by FAF images at Months 6, 12, 18, and 24 and was calculated using a MMRM model. Baseline was defined as the last available, non-missing observation prior to first study drug administration.

Time frame:
From Baseline (screening) through Month 24
Reported as:
Mean · mm^2
Mean Change in Total Area of GA Lesions in the Study Eye Through Month 24
mm^2Pegcetacoplan MonthlyPegcetacoplan EOMSham Pooled
From Baseline to Month 60.7604 ± 0.046290.8220 ± 0.043460.9838 ± 0.04666
From Month 6 to Month 120.7848 ± 0.059580.8184 ± 0.056600.9710 ± 0.05163
From Month 12 to Month 180.8004 ± 0.050340.8682 ± 0.049591.0269 ± 0.05288
From Month 18 to Month 240.7617 ± 0.66500.7499 ± 0.043720.9958 ± 0.05824
From Baseline to Month 243.1073 ± 0.148413.2586 ± 0.134203.9775 ± 0.14310
Statistical analysis
  • Pegcetacoplan Monthly vs Sham Pooled · MMRM model · p = 0.0007 · Mean difference: -0.2234 · 95% CI -0.3522 to -0.0946
  • Pegcetacoplan EOM vs Sham Pooled · MMRM model · p = 0.0116 · Mean difference: -0.1618 · 95% CI -0.2874 to -0.0361
  • Pegcetacoplan Monthly vs Sham Pooled · MMRM model · p = 0.0181 · Mean difference: -0.1862 · 95% CI -0.3406 to -0.0318
  • Pegcetacoplan EOM vs Sham Pooled · MMRM model · p = 0.0467 · Mean difference: -0.1526 · 95% CI -0.3030 to -0.0023
  • Pegcetacoplan Monthly vs Sham Pooled · MMRM model · p = 0.0019 · Mean difference: -0.2265 · 95% CI -0.3696 to -0.0834
  • Pegcetacoplan EOM vs Sham Pooled · MMRM model · p = 0.0288 · Mean difference: -0.1586 · 95% CI -0.3009 to -0.0164
  • Pegcetacoplan Monthly vs Sham Pooled · MMRM model · p = 0.0080 · Mean difference: -0.2341 · 95% CI -0.4071 to -0.0611
  • Pegcetacoplan EOM vs Sham Pooled · MMRM model · p = 0.0007 · Mean difference: -0.2459 · 95% CI -0.3886 to -0.1031
  • Pegcetacoplan Monthly vs Sham Pooled · MMRM model · p = <0.0001 · Mean difference: -0.8702 · 95% CI -1.2740 to -0.4664
  • Pegcetacoplan EOM vs Sham Pooled · MMRM model · p = 0.0003 · Mean difference: -0.7189 · 95% CI -1.1039 to -0.3339
SecondaryLS Mean Change From Baseline in Mean Threshold Sensitivity of All Points of the Study Eye at Month 24

Mean threshold sensitivity of all points was determined from the mesopic microperimetry as an assessment of the macular functional response. Microperimetry offers the option to test retinal light sensitivity while directly observing the fundus and allows for monitoring of macular function loss associated with GA progression. The microperimetry reading center overlaid the baseline FAF images with GA lesions traced by the imaging reading center and the corresponding macular integrity assessment microperimetry baseline scanning laser ophthalmoscope image and identified perilesional (within 500 microns outside the atrophy border), paralesional (beyond 500 microns outside the atrophy border), and extralesional (outside the atrophy border) loci on the microperimetry grid to determine the mean threshold sensitivity for these 3 areas. LS mean was calculated using a MMRM model. Baseline was defined as the last available, non-missing observation prior to first study drug administration.

Time frame:
Baseline (screening) and Month 24
Reported as:
Least squares mean · decibels (dB)
LS Mean Change From Baseline in Mean Threshold Sensitivity of All Points of the Study Eye at Month 24
decibels (dB)Pegcetacoplan MonthlyPegcetacoplan EOMSham Pooled
LS Mean Change From Baseline in Mean Threshold Sensitivity of All Points of the Study Eye at Month 24-3.319 ± 0.2969-3.064 ± 0.2331-2.954 ± 0.2156
SecondaryLS Mean Change From Baseline in Monocular Maximum Reading Speed of the Study Eye at Month 24

The maximum reading speed of the study eye was calculated per Minnesota Low-Vision Reading Test (MNREAD) or Radner Reading Charts user manuals, with no adjustment for reading inaccuracy. An additional step to cap resulting reading speed values at a maximum of 300 words per minute (wpm) was implemented. Maximum reading speed was calculated as the mean of the 3 highest non-zero reading speeds (or 2, or 1 value, as available), except when all wpm were calculated as 0 then the maximum reading speed was calculated as 0. LS mean was calculated using a MMRM model. Baseline was defined as the last available, non-missing observation prior to first study drug administration.

Time frame:
Baseline (screening) and Month 24
Reported as:
Least squares mean · wpm
LS Mean Change From Baseline in Monocular Maximum Reading Speed of the Study Eye at Month 24
wpmPegcetacoplan MonthlyPegcetacoplan EOMSham Pooled
LS Mean Change From Baseline in Monocular Maximum Reading Speed of the Study Eye at Month 24-22.446 ± 3.0329-17.533 ± 3.2886-16.211 ± 3.8129
SecondaryLS Mean Change From Baseline in Mean Functional Reading Independence (FRI) Index Score at Month 24

The FRI was an interviewer-administered questionnaire with 7 items on functional reading activities most relevant to GA AMD subjects. It had 1 total index score. For each FRI Index reading activity performed in the past 7 days, subjects were asked about the extent to which they required assistance beyond eyeglasses/contact lenses, including the use of low-vision aids, adjustments in the activity, or help from another subject. Mean FRI Index scores ranged from 1 (unable to do independently) to 4 (totally independent), with higher scores indicating higher functional reading independence. A negative change from baseline indicated a decrease in the FRI; disease worsening. LS mean was calculated using a MMRM model. Baseline was defined as the last available, non-missing observation prior to first study drug administration.

Time frame:
Baseline (screening) and Month 24
Reported as:
Least squares mean · score on a scale
LS Mean Change From Baseline in Mean Functional Reading Independence (FRI) Index Score at Month 24
score on a scalePegcetacoplan MonthlyPegcetacoplan EOMSham Pooled
LS Mean Change From Baseline in Mean Functional Reading Independence (FRI) Index Score at Month 24-0.287 ± 0.0563-0.379 ± 0.0536-0.273 ± 0.0554
SecondaryLS Mean Change From Baseline in Normal-Luminance Best-Corrected Visual Acuity (NL-BCVA) Score of the Study Eye at Month 24

The NL-BCVA was assessed by early treatment diabetic retinopathy study (ETDRS) chart prior to dilating the eyes at a starting distance of 4 meters and ranged from 0 (least score) to 100 (best score). If the 4-meter score was \>19 letters read correctly, the visual acuity score was the sum of total letters correctly read at 4 meters plus the addition of 30. If the 4-meter score was ≤19 letters read correctly, the visual acuity score was the sum of total letters read correctly at 4 meters and total letters read correctly at the 1-meter distance. If no letters were read correctly at either the 4-meter distance or the 1-meter distance, the visual acuity score was 0. A positive change in the value indicated improvement in visual acuity. LS mean was calculated using a MMRM model. Baseline was defined as the last available, non-missing observation prior to first study drug administration.

Time frame:
Baseline (screening) and Month 24
Reported as:
Least squares mean · ETDRS letters score
LS Mean Change From Baseline in Normal-Luminance Best-Corrected Visual Acuity (NL-BCVA) Score of the Study Eye at Month 24
ETDRS letters scorePegcetacoplan MonthlyPegcetacoplan EOMSham Pooled
LS Mean Change From Baseline in Normal-Luminance Best-Corrected Visual Acuity (NL-BCVA) Score of the Study Eye at Month 24-7.477 ± 1.0512-8.526 ± 1.0525-7.660 ± 1.0734

Adverse events

Collected over Treatment-emergent adverse events (TEAEs) were reported from first study drug administration (Day 1) up to the last visit or early termination visit, 30 days after the last study drug administration for the monthly treatment groups and 60 days after the last study drug administration for the EOM treatment groups, a maximum of 24 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pegcetacoplan Monthly: Ocular Study Eye0/213 (0%)5/213 (2.3%)100/213 (46.9%)
Pegcetacoplan EOM: Ocular Study Eye0/212 (0%)4/212 (1.9%)95/212 (44.8%)
Sham Pooled: Ocular Study Eye0/211 (0%)1/211 (0.5%)59/211 (28%)
Pegcetacoplan Monthly: Ocular Fellow Eye0/213 (0%)1/213 (0.5%)69/213 (32.4%)
Pegcetacoplan EOM: Ocular Fellow Eye0/212 (0%)0/212 (0%)56/212 (26.4%)
Sham Pooled: Ocular Fellow Eye0/211 (0%)2/211 (0.9%)65/211 (30.8%)
Pegcetacoplan Monthly: Non-ocular20/213 (9.4%)77/213 (36.2%)86/213 (40.4%)
Pegcetacoplan EOM: Non-ocular9/212 (4.2%)56/212 (26.4%)72/212 (34%)
Sham Pooled: Non-ocular8/211 (3.8%)55/211 (26.1%)67/211 (31.8%)
Most frequent serious events
Showing 10 of 205
Most frequent serious events
EventPegcetacoplan Monthly: Ocular Study EyePegcetacoplan EOM: Ocular Study EyeSham Pooled: Ocular Study EyePegcetacoplan Monthly: Ocular Fellow EyePegcetacoplan EOM: Ocular Fellow EyeSham Pooled: Ocular Fellow EyePegcetacoplan Monthly: Non-ocularPegcetacoplan EOM: Non-ocularSham Pooled: Non-ocular
PneumoniaInfections and infestations0/2130/2120/2110/2130/2120/21112/2133/2123/211
Atrial fibrillationCardiac disorders0/2130/2120/2110/2130/2120/2117/2131/2126/211
COVID-19Infections and infestations0/2130/2120/2110/2130/2120/2117/2133/2124/211
COVID-19 pneumoniaInfections and infestations0/2130/2120/2110/2130/2120/2112/2131/2124/211
Cardiac failure congestiveCardiac disorders0/2130/2120/2110/2130/2120/2113/2133/2123/211
EndophthalmitisInfections and infestations2/2133/2120/2110/2130/2122/2110/2130/2120/211
Septic shockInfections and infestations0/2130/2120/2110/2130/2120/2110/2133/2120/211
Rib fractureInjury, poisoning and procedural complications0/2130/2120/2110/2130/2120/2111/2133/2120/211
Cerebrovascular accidentNervous system disorders0/2130/2120/2110/2130/2120/2113/2131/2122/211
Myocardial infarctionCardiac disorders0/2130/2120/2110/2130/2120/2112/2130/2122/211
Most frequent other events
Showing 10 of 19
Most frequent other events
EventPegcetacoplan Monthly: Ocular Study EyePegcetacoplan EOM: Ocular Study EyeSham Pooled: Ocular Study EyePegcetacoplan Monthly: Ocular Fellow EyePegcetacoplan EOM: Ocular Fellow EyeSham Pooled: Ocular Fellow EyePegcetacoplan Monthly: Non-ocularPegcetacoplan EOM: Non-ocularSham Pooled: Non-ocular
Urinary tract infectionInfections and infestations0/2130/2120/2110/2130/2120/21123/21320/21222/211
Conjunctival haemorrhageEye disorders22/21319/21210/2112/2133/2123/2110/2130/2120/211
Visual acuity reducedEye disorders17/21320/21217/21113/21311/21219/2110/2130/2120/211
Neovascular age-related macular degenerationEye disorders20/21314/2123/2119/2135/21211/2110/2130/2120/211
HypertensionVascular disorders0/2130/2120/2110/2130/2120/21120/21316/21217/211
Vitreous floatersEye disorders17/21319/2122/2112/2135/2123/2110/2130/2120/211
Eye painEye disorders17/21316/21214/2114/2131/2122/2110/2130/2120/211
FallInjury, poisoning and procedural complications0/2130/2120/2110/2130/2120/21116/21316/2129/211
Punctate keratitisEye disorders16/2136/2120/2119/2134/2121/2110/2130/2120/211
COVID-19Infections and infestations0/2130/2120/2110/2130/2120/21115/21311/21210/211

Baseline characteristics

The intent-to-treat (ITT) analysis set included all subjects assigned to treatment.

Age, Continuous
Age, Continuous(years)Pegcetacoplan MonthlyPegcetacoplan EOMSham PooledTotal
Mean79.0 ± 7.2178.1 ± 7.8178.6 ± 7.2078.6 ± 7.41
Sex: Female, Male
Sex: Female, Male(Participants)Pegcetacoplan MonthlyPegcetacoplan EOMSham PooledTotal
Female134122136392
Male799076245
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Pegcetacoplan MonthlyPegcetacoplan EOMSham PooledTotal
White193196193582
Not Reported14121440
Unknown1337
Asian3126
Black or African American2002
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Pegcetacoplan MonthlyPegcetacoplan EOMSham PooledTotal
Hispanic or Latino57416
Not Hispanic or Latino191193192576
Not Reported17121645
Region of Enrollment
Region of Enrollment(Participants)Pegcetacoplan MonthlyPegcetacoplan EOMSham PooledTotal
United States152148153453
France15141544
Australia10141034
Germany781126
Czechia97521
Poland65920
United Kingdom25411
Italy3339
Israel3216
Netherlands3104
New Zealand1214
Spain1304
Brazil1001
GA Lesion Size [fundus autofluorescence (FAF)] in the Study Eye
GA Lesion Size [fundus autofluorescence (FAF)] in the Study Eye(millimeter square (mm^2))Pegcetacoplan MonthlyPegcetacoplan EOMSham PooledTotal
Mean8.2150 ± 3.914838.3452 ± 3.956798.1581 ± 3.697398.2394 ± 3.85283
08

Study locations

112 sites
  • Arizona Retina & Vitreous Consultants
    Phoenix, Arizona 85021, United States
  • California Retina Consultants
    Bakersfield, California 93309, United States
  • Retina Vitreous Associates Medical Group
    Beverly Hills, California 90211, United States
  • Retinal Diagnostic Center
    Campbell, California 95508, United States
  • Retina Consultants of Orange County
    Fullerton, California 92835, United States
  • Atlantis Eyecare
    Huntington Beach, California 92647, United States
  • University of California, San Diego, Jacobs Retina
    La Jolla, California 92093, United States
  • Byers Eye Institute at Stanford, Stanford School of Medicine
    Palo Alto, California 94303, United States
  • Doheny Eye Center UCLA
    Pasadena, California 91105, United States
  • Retina Consultants San Diego
    Poway, California 92064, United States
  • Retinal Consultants Med Group, Inc.
    Sacramento, California 95819, United States
  • Orange County Retina Medical Group
    Santa Ana, California 92705, United States
  • California Retina Consultants
    Santa Barbara, California 93103, United States
  • Southwest Retina Research Center, LLC
    Durango, Colorado 81301, United States
  • Colorado Retina Associates
    Golden, Colorado 80401, United States
  • Retina Group of New England
    Waterford, Connecticut 06385, United States
  • Blue Ocean Clinical Research / The Macula Center
    Clearwater, Florida 33761, United States
  • National Ophthalmic Research Institute (Retina Consultants of Southwest Florida)
    Fort Myers, Florida 33912, United States
  • Bascom Palmer Eye Institute
    Miami, Florida 33136, United States
  • Bascom Palmer Eye Institute of Naples
    Naples, Florida 34103, United States
  • Retina Specialty Institute
    Pensacola, Florida 32503, United States
  • Center for Retina and Macular Disease
    Winter Haven, Florida 33880, United States
  • Southeast Retina Center, PC
    Augusta, Georgia 30909, United States
  • Gailey Eye Clinic Retina Center
    Bloomington, Illinois 61704, United States
  • Northwestern Feinberg School of Medicine
    Chicago, Illinois 60611, United States
  • Rush University Medical Center
    Chicago, Illinois 60612, United States
  • Midwest Eye Institute
    Indianapolis, Indiana 46290, United States
  • Retina and Vitreous Associates of Kentucky, PSC dba Retina Associates of Kentucky
    Lexington, Kentucky 40509, United States
  • Retina Associates New Orleans
    Metairie, Louisiana 70006, United States
  • The Retina Care Center
    Baltimore, Maryland 21209, United States
  • The Retina Group of Washington
    Chevy Chase, Maryland 20815, United States
  • Cumberland Valley Retina Center
    Hagerstown, Maryland 21740, United States
  • Mid Atlantic Retina Specialists
    Hagerstown, Maryland 21740, United States
  • Tufts Medical Center
    Boston, Massachusetts 02116, United States
  • New England Retina Consultants
    Springfield, Massachusetts 01107, United States
  • Michigan Medicine Kellogg Eye Center
    Ann Arbor, Michigan 48105, United States
  • Associated Retinal Consultants, P.C
    Grand Rapids, Michigan 49564, United States
  • VitreoRetinal Surgery PA
    Minneapolis, Minnesota 55435, United States
  • Sierra Eye Associates
    Reno, Nevada 89502, United States
  • Retina Center of NJ, LLC
    Bloomfield, New Jersey 07003, United States
  • NJ Retina
    Toms River, New Jersey 08755, United States
  • Vision Research Center Eye Associates of NM
    Albuquerque, New Mexico 87109, United States
  • Ophthalmic Consultants of Long Island
    Lynbrook, New York 11563, United States
  • New York Eye and Ear Infirmary of Mount Sinai
    New York, New York 10003, United States
  • Vitreous Retina Macula Consultants of NY
    New York, New York 10022, United States
  • Duke University, Duke Eye Center
    Durham, North Carolina 27710, United States
  • Research - Retina Vitreous Center
    Edmond, Oklahoma 73013, United States
  • Oregon Retina, LLP
    Eugene, Oregon 97405, United States
  • Mid Atlantic Retina
    Bethlehem, Pennsylvania 18017, United States
  • Retina Vitreous Consultants
    Monroeville, Pennsylvania 15146, United States
  • Mid Atlantic Retina, Wills Eye Hospital
    Philadelphia, Pennsylvania 19107, United States
  • AIO Visionary Eye Care
    West Mifflin, Pennsylvania 15122, United States
  • Charles Retina Institute
    Germantown, Tennessee 38138, United States
  • Tennessee Retina, PC
    Nashville, Tennessee 37203, United States
  • Retina Research Institute of Texas
    Abilene, Texas 79606, United States
  • Texas Retina Associates
    Dallas, Texas 75231, United States
  • Houston Eye Associates
    Houston, Texas 77025, United States
  • Retina Consultants of Houston, PA
    Houston, Texas 77030, United States
  • San Antonia Eye Center
    San Antonio, Texas 78215, United States
  • Medical Center Ophthalmology Associates
    San Antonio, Texas 78240, United States
  • Retina Associates of South Texas
    San Antonio, Texas 78240, United States
  • Retinal Consultants of San Antonio
    San Antonio, Texas 78240, United States
  • Brown Retina Institute
    San Antonio, Texas 78251, United States
  • Strategic Clinical Research Group
    Willow Park, Texas 76087, United States
  • University of Utah - John A. Moran Center
    Salt Lake City, Utah 84132, United States
  • Emerson Clinical Research Institute
    Falls Church, Virginia 22046, United States
  • University of Wisconsin
    Madison, Wisconsin 53705, United States
  • Marsden Eye Specialist
    Parramatta, New South Wales 2150, Australia
  • Adelaide Eye & Retina Clinic
    Adelaide, South Australia 5000, Australia
  • Save Sight Institute
    Sydney, South Block 2000, Australia
  • Lions Eye Institute
    Nedlands, Western Australia 6009, Australia
  • Strathfield Retina Clinic
    Strathfield, 2135, Australia
  • Sydney West Retina
    Westmead, 2145, Australia
  • UNIFESP - Federal University
    São Paulo, 04021-001, Brazil
  • UHN Toronto Western Hospital
    Toronto, Ontario M5T 2S8, Canada
  • AXON Clinical S.R.O
    Praha, 150 00, Czechia
  • Gemini Eye Clinic
    Zlín, 76001, Czechia
  • CHU Dijon
    Bordeaux, 21 079, France
  • CHU de Bordeaux
    Bordeaux, 33076, France
  • Centre Hospitalier Intercommunal de Créteil
    Créteil, 94010, France
  • Hopital Lariboisière
    Paris, 75010, France
  • CHNO des Quinze-Vingts
    Paris, 75012, France
  • Centre Ophtalmologique d'Imagerie et Laser
    Paris, 75015, France
  • CHU de Strasbourg Hopital Civil
    Strasbourg, 67091, France
  • Clinique du Val d'Ouest
    Écully, 69130, France
  • Universitäts-Augenklinik Bonn
    Bonn, 53127, Germany
  • University Opthalmology Clinic
    Freiburg im Breisgau, 79106, Germany
  • Universitätsmedizin Göttingen Georg-August-Universität
    Göttingen, 37075, Germany
  • Universitätsklinikum Schleswig-Holstein
    Lübeck, 23538, Germany
  • Augenklinik der LMU München
    München, 80336, Germany
  • Augenzentrum am St. Franziskus-Hospital
    Münster, 48145, Germany
  • Universitäts-Augenklinik
    Münster, 48149, Germany
  • STZ Eyetrial
    Tübingen, 72076, Germany
  • Rambam Medical Centre
    Haifa, 3109601, Israel
  • Carmel Medical Center
    Haifa, 3436212, Israel
  • Hadassah Medical Center
    Jerusalem, 91120, Israel
  • Ospedale San Raffaele
    Milano, 20132, Italy
  • Luigi Sacco Hospital
    Milano, 20157, Italy
  • IRCCS Fondazione G.B. Bietti
    Roma, 128, Italy
  • Academisch Medisch Centrum
    Amsterdam, 1105 AZ, Netherlands

Showing the first 100 of 112 sites across 14 countries. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2018 to primary completion in Jun 2021, 33 months.

Results were first posted in Jul 2023, 2 years after primary completion. A results delay was requested in Jun 2022.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 20, 2018
First posted
May 15, 2018
StartActual
Aug 31, 2018
Primary completionActual
Jun 28, 2021
CompletionActual
Jun 28, 2022
Results delay requested
Jun 20, 2022
Results first posted
Jul 6, 2023
Last update
Jul 6, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 6, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03525613
Responsible party
Sponsor
First posted
May 15, 2018
Start date
Aug 31, 2018
Primary completion
Jun 28, 2021
Completion
Jun 28, 2022
Results posted
Jul 6, 2023
Last update
Jul 6, 2023

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pegcetacoplan

Start the discussion